Ledipasvir/Sofosbuvir

Phase 3Completed

4 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hepatitis C, Chronic

Conditions

Hepatitis C, Chronic, Cirrhosis, Decompensated

Trial Timeline

Jan 1, 2016 → Jun 1, 2018

NCT ID

NCT02597166

About Ledipasvir/Sofosbuvir

Ledipasvir/Sofosbuvir is a phase 3 stage product being developed by Gilead Sciences for Hepatitis C, Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT02597166. Target conditions include Hepatitis C, Chronic, Cirrhosis, Decompensated.

What happened to similar drugs?

20 of 20 similar drugs in Hepatitis C, Chronic were approved

Approved (20) Terminated (8) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Pegylated Interferon + RibavirinAstellas PharmaApproved

✅Glecaprevir-pibrentasvirAbbVieApproved

✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved

✅PTV/r/OBV/DSVAbbVieApproved

✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved

✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02683005	Phase 1	Completed	Sep 1, 2016	Feb 3, 2020	Hepatitis C
NCT02597166	Phase 3	Completed	Jan 1, 2016	Jun 1, 2018	Hepatitis C, Chronic

Competing Products

20 competing products in Hepatitis C, Chronic

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
IVA337 + IVA337 + Placebo	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
Pegasys® + Pegasys®	Chugai Pharmaceutical	Approved	43
peginterferon alfa-2a + rivavirin	Chugai Pharmaceutical	Phase 3	40
SOF + COPE	Chugai Pharmaceutical	Pre-clinical	26
Colesevelam Hcl	Daiichi Sankyo	Phase 2	35
ASP9831 + Placebo	Astellas Pharma	Phase 2	35
FK788	Astellas Pharma	Phase 2	35
MK-2248	Merck	Phase 1	29
Interferon alfacon-1	Astellas Pharma	Phase 3	40
Pegylated Interferon + Ribavirin	Astellas Pharma	Approved	35
Tacrolimus + steroids, monoclonal anti-IL2R antibody	Astellas Pharma	Phase 2	35
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	29
Dolutegravir + Methadone	Shionogi	Phase 1	29
Clevudine + Adefovir	Eisai	Phase 3	40